摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-aza-2'-deoxycytidine mesylate | 879492-57-6

中文名称
——
中文别名
——
英文名称
5-aza-2'-deoxycytidine mesylate
英文别名
decitabine mesylate;4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one;methanesulfonic acid
5-aza-2'-deoxycytidine mesylate化学式
CAS
879492-57-6
化学式
CH4O3S*C8H12N4O4
mdl
——
分子量
324.315
InChiKey
CLSXTOVZZQEQIL-FPKZOZHISA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -2.63
  • 重原子数:
    21
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    184
  • 氢给体数:
    4
  • 氢受体数:
    7

ADMET

毒理性
  • 在妊娠和哺乳期间的影响
◉ 母乳喂养期间使用总结:大多数来源认为,在母亲抗肿瘤药物治疗期间,母乳喂养是禁忌的。在间歇性去氧脱氧核苷治疗期间,如果有一个适当的哺乳戒断期,可能可以安全地进行母乳喂养;制造商建议在最后一次剂量后戒断期为1周。化疗可能会不利地影响母乳的正常微生物组和化学成分。在怀孕期间接受化疗的妇女更有可能在哺乳婴儿时遇到困难。 ◉ 对哺乳婴儿的影响:截至修订日期,没有找到相关的已发布信息。 ◉ 对泌乳和母乳的影响:对74名在怀孕第二或第三季度在一家中心接受癌症化疗的妇女进行了电话随访研究,以确定她们产后是否成功进行母乳喂养。只有34%的妇女能够完全用母乳喂养她们的婴儿,而66%的妇女报告遇到母乳喂养困难。这与22位在怀孕期间被诊断但未接受化疗的母亲91%的母乳喂养成功率形成了对比。其他具有统计学意义的相关性包括:1)有哺乳困难的母亲平均接受了5.5个周期的化疗,而没有困难的母亲平均接受了3.8个周期;2)有哺乳困难的母亲在怀孕期间平均提前3.4周接受了第一次化疗周期。在接受了含氟尿嘧啶方案的9名妇女中,有8名遇到了哺乳困难。
◉ Summary of Use during Lactation:Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy. It might be possible to breastfeed safely during intermittent decitabine therapy with an appropriate period of breastfeeding abstinence; the manufacturer recommends an abstinence period of 1 week after the last dose. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk. Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:A telephone follow-up study was conducted on 74 women who received cancer chemotherapy at one center during the second or third trimester of pregnancy to determine if they were successful at breastfeeding postpartum. Only 34% of the women were able to exclusively breastfeed their infants, and 66% of the women reported experiencing breastfeeding difficulties. This was in comparison to a 91% breastfeeding success rate in 22 other mothers diagnosed during pregnancy, but not treated with chemotherapy. Other statistically significant correlations included: 1) mothers with breastfeeding difficulties had an average of 5.5 cycles of chemotherapy compared with 3.8 cycles among mothers who had no difficulties; and 2) mothers with breastfeeding difficulties received their first cycle of chemotherapy on average 3.4 weeks earlier in pregnancy. Of the 9 women who received a fluorouracil-containing regimen, 8 had breastfeeding difficulties.
来源:Drugs and Lactation Database (LactMed)

SDS

SDS:ca9588988084dc00111d226f2164aa67
查看

反应信息

  • 作为产物:
    描述:
    甲烷磺酸地西他滨甲醇 为溶剂, 反应 1.17h, 生成 5-aza-2'-deoxycytidine mesylate
    参考文献:
    名称:
    Salts of 5-azacytidine
    摘要:
    本发明涉及5-氮杂胞苷盐以及合成所述盐的方法。还提供了含有5-氮杂胞苷盐的药物组成物和使用该盐或药物组成物治疗疾病的方法,例如癌症和血液疾病。
    公开号:
    US20060063735A1
点击查看最新优质反应信息

文献信息

  • Salts of decitabine
    申请人:Redkar Sanjeev
    公开号:US20060069060A1
    公开(公告)日:2006-03-30
    The present invention relates to salts of decitabine as well as methods for synthesizing the salts described herein. Pharmaceutical compositions and methods of using the decitabine salts are also provided, including methods of administering the salts or pharmaceutical compositions thereof to treat conditions, such as cancer and hematological disorders.
    本发明涉及脱氧胞苷盐以及合成所述盐的方法。还提供了脱氧胞苷盐的药用组合物和使用方法,包括将这些盐或药用组合物用于治疗癌症和血液学疾病等疾病的方法。
  • Oral administration of decitabine salt
    申请人:Redkar Sanjeev
    公开号:US20060074046A1
    公开(公告)日:2006-04-06
    The present invention relates to salts of decitabine as well as methods for synthesizing the salts described herein. Pharmaceutical compositions and methods of using the decitabine salts are also provided, including methods of orally administering the salts or pharmaceutical compositions thereof to treat conditions, such as cancer and hematological disorders.
    本发明涉及地西他滨的盐类以及合成所述盐类的方法。本发明还提供了使用地西他滨盐的药物组合物和方法,包括口服该盐或其药物组合物治疗癌症和血液病等疾病的方法。
  • SALTS OF 5-AZACYTIDINE
    申请人:SuperGen, Inc.
    公开号:EP1788874A2
    公开(公告)日:2007-05-30
  • SALTS OF DECITABINE
    申请人:SuperGen, Inc.
    公开号:EP1793675A2
    公开(公告)日:2007-06-13
  • Salts of 5-Azacytidine
    申请人:Redkar Sanjeev
    公开号:US20100062992A1
    公开(公告)日:2010-03-11
    The present invention relates to salts of 5-azacytidine as well as methods for synthesizing the salts described herein. Pharmaceutical compositions and methods of using the 5-azacytidine salts are also provided, including methods of administering the salts or pharmaceutical compositions thereof to treat conditions, such as cancer and hematological disorders.
查看更多